Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | NT5E | P21589 | 2/20 | 0.56 |
| ▸ | TYMP | P19971 | 1/20 | 0.52 |
| ▸ | ADK | P55263 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18526554 | 0.90 | ADORA3 (0.80) | ADORA3LMNATP53NT5ECA1 | |
| SCHEMBL16160996 | 0.88 | ADORA3 (0.74) | ADORA3LMNATP53NT5ECA1 | |
| SCHEMBL16619900 | 0.88 | ADORA3 (0.64) | ADORA3NT5ECA1CA2CA4 | |
| SCHEMBL741776 | 0.87 | LMNA (0.78) | ADORA3LMNATP53NT5EADORA2A | |
| SCHEMBL741775 | 0.87 | LMNA (0.78) | ADORA3LMNATP53NT5EADORA2A | |
| SCHEMBL7531797 | 0.87 | ADORA3 (0.66) | ADORA3LMNATP53NT5ETYMP | |
| SCHEMBL29936666 | 0.87 | ADORA3 (0.78) | ADORA3LMNANT5ECA1CA2 | |
| SCHEMBL8622533 | 0.87 | ADORA3 (0.78) | ADORA3LMNANT5ECA1CA2 | |
| SCHEMBL15071488 | 0.86 | RNASEL (0.68) | NT5ERNASELADORA1 | |
| SCHEMBL15248814 | 0.86 | RNASEL (0.68) | NT5ERNASELADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030856-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6740644-B2 | ADENOSINE DERIVATIVES, AGONISTS AT THE ADENOSINE A1 RECEPTOR | SMITHKLINE BEECHAM CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20030158146-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | US | disclosed |
| US-6544960-B1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-08 | — | — | US | disclosed |
| EP-0901499-B1 | ADENOSINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2002-04-10 | — | — | EP | disclosed |
| EP-1030856-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | disclosed |
| US-5998388-A | N6-PHENYL-SUBSTITUTED | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999024451-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
| EP-0901499-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043300-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158146-A1 | Chemical compounds | CNR1, ADORA3, ADORA1 | ADORA3 2/4885LMNA 1359/4885TP53 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.